Business Wire

AL-ADTRAN

23.5.2024 14:01:26 CEST | Business Wire | Press release

Share
Adtran celebrates 75 years of Oscilloquartz network timing innovation

Adtran today announced that this month marks the 75th anniversary of Oscilloquartz. Founded in 1949, Oscilloquartz has evolved into a global leader in PNT network timing technology, setting numerous industry benchmarks throughout its history. The company offers precision synchronization solutions that empower customers to overcome timing challenges in sectors from telecoms to critical defense infrastructure. Over the years, Oscilloquartz has consistently led the way with groundbreaking achievements, such as introducing the industry’s first optical cesium atomic clocks with optical pumping technology, which provide unparalleled accuracy and reliability. This month also commemorates 10 years since Oscilloquartz was acquired by ADVA, now part of Adtran, helping it expand its portfolio of cost-effective timing technologies and establish the leading assured PNT platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523252321/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s Oscilloquartz timing technology is playing a key role in helping organizations strengthen critical network infrastructure. (Photo: Business Wire)

“Celebrating 75 years of Oscilloquartz, alongside a decade since our integration into the Adtran family, represents a remarkable achievement. The dual anniversary highlights our enduring commitment to timing innovation and quality. Throughout these decades, we’ve navigated the evolving landscape from frequency solutions for legacy SONET/SDH to highly accurate frequency and time solutions for packet-based networks. Our dedication has enabled us to offer scalable technology that ensures robust timing, with or without satellite signals,” said Gil Biran, GM of Oscilloquartz, Adtran. “From pioneering the integration of synchronization delivery and assurance to bringing timing closer to end applications through our compact, low-power devices, including our latest family of OSAinside products, our portfolio has consistently addressed our customers’ key challenges. More recently, the introduction of the first commercial optical cesium atomic clocks was another major leap, significantly enhancing the precision and stability of network timing while substantially extending lifespan.”

Since its inception, Oscilloquartz has led the field in network synchronization, setting standards with the industry’s first commercial magnetic cesium atomic clock in 1966 and spearheading telecoms timing solutions in 1978. In 1982, it transformed the market by introducing the first high-performance quartz oscillators and resonators, which played a key role in developing the European Digital Cesium Standard in 1988. After its acquisition in 2014, Oscilloquartz expanded its global presence, with leading service providers adopting its products. It also provided customized solutions across metrology, finance and national defense sectors. Its leadership in cesium clock technology won support for its R&D initiatives from the European Space Agency. Continuing its legacy of innovation, Oscilloquartz recently enhanced the resiliency of GPS/GNSS systems with its Iridium®-based Satellite Time and Location (STL) technology solutions, leveraging low-Earth orbit satellite signals for more reliable, secure synchronization even in challenging environments.

“This historic anniversary is a moment to appreciate Oscilloquartz’s incredible journey, from its initial project at the astronomical observatory in Neuchâtel 70 years ago to the forefront of timing technology today,” commented Christoph Glingener, CTO of Adtran. “Over the last decade, the integration with ADVA and then Adtran has enriched Oscilloquartz’s offerings through the combined expertise of our teams. This era saw the debut of compact and cost-effective Oscilloquartz synchronization devices, delivering unmatched precision at the network edge. Its core grandmasters set new industry benchmarks with their 10GbE support and hardware timestamping. Together with Oscilloquartz’s optical atomic cesium clocks, they create a SePRTC+, guaranteeing accurate, reliable timing even during GNSS disruptions for up to 100 days. This combination of the industry’s most scalable family of grandmasters based on zero-trust architecture, coupled with optical pumping technology, sets Oscilloquartz apart today. As part of the Adtran family, Oscilloquartz will continue its legacy of excellence, keeping customers at the forefront of synchronization technology.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523252321/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye